For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers:
Painkillers only: Only a simple analgesic effect, but no anti-inflammatory function, such as acetaminophen, tramadol. Acetaminophen side effects, but the analgesic effect is relatively weak, mainly for mild to moderate pain; tramadol analgesic effect is strong, but also side effects are larger, mainly gastrointestinal side effects such as nausea, vomiting and so on.
NSAIDs: With both anti-inflammatory and analgesic effect, suitable for inflammatory pain, for the acute phase of osteoarthritis, joint swelling of the patients to relieve symptoms better. These drugs may lead to nausea, vomiting and other gastrointestinal discomfort, but also increase the risk of gastrointestinal bleeding, so patients with gastro duodenal ulcer in the application of these drugs should consult a digestive physician, plus gastric mucosal protection Drugs or antacid drugs.
Medicines for Osteoarthritis Pain are available as pills, syrups, creams or lotions, or they are injected into a joint.
Scope of the Report:
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement.
The USA osteoarthritis pain drugs market is very concerted market; the revenue of eleven manufacturers accounts about 88% of the total revenue in 2016. The high-end products mainly come from USA and Europe.
The leading manufactures mainly are Johnson & Johnson, Pfizer and GlaxoSmithKline. Johnson & Johnson is the largest manufacturer; its revenue of USA market exceeds 27% in 2016. The next is Pfizer and GlaxoSmithKline.
The worldwide market for Osteoarthritis Pain Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Osteoarthritis Pain Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Johnson & Johnson
- Pfizer
- GlaxoSmithKline
- Mylan
- Lilly
- Sanofi
- Abbott Laboratories
- Bayer
- Almatica Pharma
- TEVA
- Iroko Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Oral
- Injection
- External
Market Segment by Applications, can be divided into
- Medical Care
- Personal Care
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Osteoarthritis Pain Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Osteoarthritis Pain Drugs, with price, sales, revenue and global market share of Osteoarthritis Pain Drugs in 2017 and 2018.
Chapter 3, the Osteoarthritis Pain Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Osteoarthritis Pain Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Osteoarthritis Pain Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Osteoarthritis Pain Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.